$DCGO
DocGo Inc. Stock $dcgo

$dcgo Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023037709 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$125.5M	$113.0M	$117.9M
YoY Change	14.58%	-4.15%	137.26%
Cost Of Revenue	$83.62M	$81.23M	$77.99M
YoY Change	19.15%	4.15%	117.47%
Gross Profit	$41.87M	$31.78M	$39.90M
YoY Change	6.42%	-20.37%	188.57%
Gross Profit Margin	33.37%	28.12%	33.85%
Selling, General & Admin	$31.48M	$29.53M	$25.12M
YoY Change	22.8%	17.55%	95.04%
% of Gross Profit	75.19%	92.92%	62.95%
Research & Development	$2.574M	$1.864M	$1.142M
YoY Change	124.19%	63.21%	100.55%
% of Gross Profit	6.15%	5.86%	2.86%
Depreciation & Amortization	$3.831M	$1.483M	$2.201M
YoY Change	88.0%	-32.64%	37.76%
% of Gross Profit	9.15%	4.67%	5.52%
Operating Expenses	$37.89M	$119.9M	$28.46M
YoY Change	31.45%	321.29%	89.17%
Operating Profit	$3.981M	-$6.903M	$11.44M
YoY Change	-62.16%	-160.32%	-1040.0%
Interest Expense	$431.3K	$908.8K	-$282.0K
YoY Change	-90.63%	-422.32%	145.15%
% of Operating Profit	10.83%		-2.46%
Other Income/Expense, Net	-$920.1K	$214.9K	-$4.253K
YoY Change	-5982.74%	-5152.43%
Pretax Income	$988.6K	-$6.049M	$9.813M
YoY Change	-91.81%	-161.64%	-593.35%
Income Tax	-$355.1K	-$2.130M	$440.2K
% Of Pretax Income	-35.92%		4.49%
Net Earnings	-$2.011M	-$3.466M	$10.63M
YoY Change	-115.79%	-132.6%	-733.34%
Net Earnings / Revenue	-1.6%	-3.07%	9.02%
Basic Earnings Per Share	-$0.02	-$0.03	$0.11
Diluted Earnings Per Share	-$0.02	-$0.03	$91.91K
COMMON SHARES
Basic Shares Outstanding	103.5M shares	102.5M shares	100.2M shares
Diluted Shares Outstanding	103.6M shares	102.6M shares	115.7M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$109.2M	$120.1M	$188.4M
YoY Change	-44.91%	-36.26%	37570.78%
Cash & Equivalents	$109.2M	$120.1M	$188.4M
Short-Term Investments
Other Short-Term Assets	$6.787M	$6.737M	$3.649M
YoY Change	28.41%	84.63%	1558.73%
Inventory
Prepaid Expenses
Receivables	$118.5M	$131.6M	$76.17M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$234.4M	$258.4M	$268.2M
YoY Change	-14.96%	-3.65%	37145.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.19M	$21.73M	$25.25M
YoY Change	64.37%	-13.93%
Goodwill	$47.82M	$47.67M
YoY Change
Intangibles	$38.05M	$38.94M
YoY Change
Long-Term Investments	$392.1K	$482.7K	$520.1K
YoY Change	-36.69%	-7.19%	-99.55%
Other Assets	$29.39M	$3.351M	$11.99M
YoY Change	144.78%	-72.06%
Total Long-Term Assets	$155.8M	$149.2M	$57.03M
YoY Change	177.41%	161.55%	-50.42%
TOTAL ASSETS
Total Short-Term Assets	$234.4M	$258.4M	$268.2M
Total Long-Term Assets	$155.8M	$149.2M	$57.03M
Total Assets	$390.3M	$407.5M	$325.2M
YoY Change	17.61%	25.32%	181.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.691M	$19.03M	$15.12M
YoY Change	-48.2%	25.84%	25101.55%
Accrued Expenses	$36.63M	$30.54M	$38.81M
YoY Change	-7.26%	-21.29%	55336.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$1.026M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$3.414M	$649.8K	$3.856M
YoY Change	5.97%	-83.15%
Total Short-Term Liabilities	$91.76M	$109.0M	$60.99M
YoY Change	58.38%	78.67%	33784.72%
LONG-TERM LIABILITIES
Long-Term Debt	$7.507M	$7.334M	$7.574M
YoY Change	18.68%	-3.17%
Other Long-Term Liabilities	$7.162M	$7.315M	$16.37M
YoY Change	-45.75%	-55.3%	52.8%
Total Long-Term Liabilities	$14.67M	$14.65M	$23.94M
YoY Change	-24.88%	-38.81%	123.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$91.76M	$109.0M	$60.99M
Total Long-Term Liabilities	$14.67M	$14.65M	$23.94M
Total Liabilities	$110.5M	$123.6M	$93.21M
YoY Change	30.38%	32.63%	755.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.73M	-$32.37M
YoY Change
Common Stock	$10.38K	$10.29K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$279.8M	$278.7M	$232.0M
YoY Change
Total Liabilities & Shareholders Equity	$390.3M	$407.5M	$325.2M
YoY Change	17.61%	25.32%	181.0%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.011M	-$3.466M	$10.63M
YoY Change	-115.79%	-132.6%	-733.34%
Depreciation, Depletion And Amortization	$3.831M	$1.483M	$2.201M
YoY Change	88.0%	-32.64%	37.76%
Cash From Operating Activities	$10.69M	-$23.12M	$18.26M
YoY Change	-10.31%	-226.57%	-1419.53%
INVESTING ACTIVITIES
Capital Expenditures	$2.110M	$1.976M	-$1.137M
YoY Change	-356.96%	-273.79%	-10.84%
Acquisitions		-$1.575M
YoY Change
Other Investing Activities	-$21.62M	$1.692M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$23.73M	-$1.689M	-$1.137M
YoY Change	2789.96%	48.59%	-10.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$374.3K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.760M	-$11.95M	2.497M
YoY Change	-737.31%	-578.66%	-553.48%
NET CHANGE
Cash From Operating Activities	10.69M	-$23.12M	18.26M
Cash From Investing Activities	-23.73M	-$1.689M	-1.137M
Cash From Financing Activities	8.760M	-$11.95M	2.497M
Net Change In Cash	-4.275M	-$36.59M	19.62M
YoY Change	-143.95%	-286.45%	-711.2%
FREE CASH FLOW
Cash From Operating Activities	$10.69M	-$23.12M	$18.26M
Capital Expenditures	$2.110M	$1.976M	-$1.137M
Free Cash Flow	$8.583M	-$25.09M	$19.40M
YoY Change	-32.64%	-229.34%	-17919.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39618
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	DocGo Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	984864	usd
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2515483
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	35 West 35th Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 6
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2023Q1	dei	City Area Code CityAreaCode	(844)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	443-6246
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	DCGO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103473896	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120056897	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157335323	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3780545	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7818702	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	131599567	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	102995397	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	4480344	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6737378	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6269841	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	258393842	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	271080905	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21729460	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21258175	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	38939054	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22969246	usd
CY2023Q1	us-gaap	Goodwill Goodwill	47668654	usd
CY2022Q4	us-gaap	Goodwill Goodwill	38900413	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	7461821	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6773751	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9375132	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9074277	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9170429	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9039663	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	482691	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	597977	usd
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	10973522	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	9957967	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3350571	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3625254	usd
CY2023Q1	us-gaap	Assets Assets	407545176	usd
CY2022Q4	us-gaap	Assets Assets	393277628	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	19028065	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21582866	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30544082	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31573031	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	649808	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	664913	usd
CY2023Q1	dcgo	Due From Related Party Current DueFromRelatedPartyCurrent	-27198044	usd
CY2022Q4	dcgo	Due From Related Party Current DueFromRelatedPartyCurrent	-26244133	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	26428272	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	10555540	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2353383	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2325024	usd
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	4480344	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2773029	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2732639	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	108974683	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	100158490	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1272415	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1236601	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7315226	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7040982	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6061828	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5914164	usd
CY2023Q1	us-gaap	Liabilities Liabilities	123624152	usd
CY2022Q4	us-gaap	Liabilities Liabilities	114350237	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102932174	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102932174	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102411162	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102411162	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	10293	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	10241	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	310049864	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	301451435	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32367602	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28972216	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	741206	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	278677419	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	273230666	usd
CY2023Q1	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	5243605	usd
CY2022Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	5696725	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	283921024	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	278927391	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	407545176	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	393277628	usd
CY2023Q1	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	113002703	usd
CY2022Q1	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	117891552	usd
CY2023Q1	dcgo	Cost Of Revenues CostOfRevenues	81226498	usd
CY2022Q1	dcgo	Cost Of Revenues CostOfRevenues	77987573	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29220317	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23860616	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3649329	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2201021	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	3638321	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	1347983	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1863579	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1141833	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	307246	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1257961	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	119905290	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	107796987	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6902587	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	10094565	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	809172	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-135606	usd
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	58749	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-115286	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-83341	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-54839	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	214880	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4253	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	853927	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-281949	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6048660	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9812616	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2129870	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	440179	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3918790	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	9372437	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-453120	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1257257	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3465670	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10629694	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	243658	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5863	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3222012	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	10623831	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102579291	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100177082	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102579291	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115652049	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	227057024	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	374344	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1422937	usd
CY2022Q1	dcgo	Stock Issued During Period Value Equity Cost StockIssuedDuringPeriodValueEquityCost	-19570	usd
CY2022Q1	dcgo	Noncontrolling Interest Contribution NoncontrollingInterestContribution	2063000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5863	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1257257	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	10629694	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	240264309	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	278927391	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	249715	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	167175	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	8181591	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	70284	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-453120	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	243658	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3465670	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	283921024	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3918790	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	9372437	usd
CY2023Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	1482610	usd
CY2022Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	711878	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1365636	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	633363	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	801083	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	855781	usd
CY2023Q1	dcgo	Loss On Disposal Of Assets LossOnDisposalOfAssets	54839	usd
CY2023Q1	dcgo	Deferred Tax Asset DeferredTaxAsset	1015555	usd
CY2023Q1	dcgo	Gain On Equity Method Investment GainOnEquityMethodInvestment	115286	usd
CY2022Q1	dcgo	Gain On Equity Method Investment GainOnEquityMethodInvestment	68995	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1902587	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1154235	usd
CY2023Q1	dcgo	Stock Based Compensation StockBasedCompensation	8450016	usd
CY2022Q1	dcgo	Stock Based Compensation StockBasedCompensation	1422937	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	58749	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-70284	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24668050	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1061709	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	174059	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1537550	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-274683	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2188242	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2581796	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-671744	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1471551	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3063148	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23117951	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18264682	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1976075	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	602416	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1405444	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	534624	usd
CY2023Q1	dcgo	Acquisition Of Leased Assets AcquisitionOfLeasedAssets	-1574604	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	117420	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1689495	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1137040	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	129370	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	138151	usd
CY2023Q1	dcgo	Due To Seller DueToSeller	11494549	usd
CY2022Q1	dcgo	Due To Seller DueToSeller	160250	usd
CY2022Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2063000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	416890	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	374344	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	19570	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	744030	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	622575	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11951059	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2496798	usd
CY2023Q1	dcgo	Effect Of Exchange Rate Changes On Cash And Cash Equivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents	168149	usd
CY2022Q1	dcgo	Effect Of Exchange Rate Changes On Cash And Cash Equivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents	-5863	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-36590356	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19618577	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164109074	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179105730	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127518718	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198724307	usd
CY2023Q1	dcgo	Cash Paid For Interest CashPaidForInterest	32827	usd
CY2022Q1	dcgo	Cash Paid For Interest CashPaidForInterest	68222	usd
CY2023Q1	dcgo	Cash Paid For Interest On Finance Lease Liabilities CashPaidForInterestOnFinanceLeaseLiabilities	126584	usd
CY2022Q1	dcgo	Cash Paid For Interest On Finance Lease Liabilities CashPaidForInterestOnFinanceLeaseLiabilities	153327	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	40050	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	440179	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	926468	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	722716	usd
CY2023Q1	dcgo	Gain From Ppp Loans Forgiveness GainFromPPPLoansForgiveness	-150079	usd
CY2023Q1	dcgo	Reconciliation Of Cash ReconciliationOfCash	120056897	usd
CY2022Q1	dcgo	Reconciliation Of Cash ReconciliationOfCash	188353909	usd
CY2023Q1	dcgo	Noncash Investing Activities Acquisition Of Business Funded By Acquisition Payable NoncashInvestingActivitiesAcquisitionOfBusinessFundedByAcquisitionPayable	-7461821	usd
CY2022Q1	dcgo	Noncash Investing Activities Acquisition Of Business Funded By Acquisition Payable NoncashInvestingActivitiesAcquisitionOfBusinessFundedByAcquisitionPayable	-10370398	usd
CY2023Q1	dcgo	Total Cash And Restricted Cash Shown In Statement Of Cash Flows TotalCashAndRestrictedCashShownInStatementOfCashFlows	127518718	usd
CY2022Q1	dcgo	Total Cash And Restricted Cash Shown In Statement Of Cash Flows TotalCashAndRestrictedCashShownInStatementOfCashFlows	198724307	usd
CY2023Q1	dcgo	Noncash Investing Activities Acquisitions Of Business Funded By Acquisition Payable NoncashInvestingActivitiesAcquisitionsOfBusinessFundedByAcquisitionPayable	19473805	usd
CY2023Q1	us-gaap	Share Price SharePrice	0.0001
CY2023Q1	dcgo	Net Proceeds NetProceeds	158000000	usd
CY2023Q1	dcgo	Cash Held Trust Account CashHeldTrustAccount	43400000	usd
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	9600000	usd
CY2023Q1	dcgo	Underwriters Fees UnderwritersFees	114600000	usd
CY2023Q1	dcgo	Transaction Fees Net TransactionFeesNet	10400000	usd
CY2022Q1	dcgo	Percentage Of Accounts Receivable PercentageOfAccountsReceivable	0.17	pure
CY2023Q1	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	243658	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to revenue recognition, the allowance for doubtful accounts, stock based compensation, calculations related to the incremental borrowing rate for the Company’s lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, reserve for losses within the Company’s insurance deductibles, income taxes, and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.19	pure
CY2023Q1	us-gaap	Investment Company Total Return Unaffected By Restricted Transaction InvestmentCompanyTotalReturnUnaffectedByRestrictedTransaction	0.18	pure
CY2022Q1	us-gaap	Investment Company Total Return Unaffected By Restricted Transaction InvestmentCompanyTotalReturnUnaffectedByRestrictedTransaction	0.10	pure
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications of amounts previously reported have been made to the accompanying unaudited Condensed Consolidated Financial Statements to maintain consistency between periods presented. The reclassifications had no impact on previously reported net income or retained earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	4880746	usd
CY2022Q4	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	8125966	usd
CY2022	us-gaap	Other Expenses OtherExpenses	2000000	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	1080000	usd
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	3000000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2921958	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3465670	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10629694	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102579291	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100177082	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1236473	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	14569654	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102579291	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115652049	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9337239	shares
CY2021Q4	dcgo	National Providers Association Llc Description NationalProvidersAssociationLLCDescription	the Company acquired a 20% interest in National Providers Association, LLC (“NPA”) for $30,000. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” in the unaudited Condensed Consolidated Balance Sheets. Changes in value of NPA are recorded in “Gain (loss) on equity method investment” in the unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions. Effective December 21, 2021, three members withdrew from NPA resulting in the remaining two members obtaining the remaining ownership percentage. Since December 31, 2021, DocGo has owned 50% of NPA.
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31774910	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29782188	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10045450	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8524013	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21729460	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21258175	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1482610	usd
CY2022Q1	us-gaap	Depreciation Depreciation	711878	usd
CY2022Q4	dcgo	Gain On Bargain Purchase GainOnBargainPurchase	1593612	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	229937	usd
CY2023Q1	dcgo	Insurance Deposit InsuranceDeposit	48979760	usd
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1000000	usd
CY2023Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	17279201	usd
CY2023Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	1333333	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	26377730	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Asset Current BusinessCombinationContingentConsiderationAssetCurrent	94970024	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9796233	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	23264637	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	1761911	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	9648473	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	29167150	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	73638404	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	2288289	usd
CY2023Q1	dcgo	Due To Seller Business Combination DueToSellerBusinessCombination	12377494	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	6476000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	21141783	usd
CY2023Q1	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	42473403	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	94970024	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	2921958	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	35299136	usd
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	47668654	usd
CY2022Q4	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Balance ValuationAllowanceForImpairmentOfRecognizedServicingAssetsBalance	38900413	usd
CY2023Q1	us-gaap	Goodwill Transfers GoodwillTransfers	8642190	usd
CY2023Q1	dcgo	Cumulative Translation Adjustment Net Of Tax Period CumulativeTranslationAdjustmentNetOfTaxPeriod	126051	usd
CY2023Q1	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Balance ValuationAllowanceForImpairmentOfRecognizedServicingAssetsBalance	47668654	usd
CY2023Q1	dcgo	Increase Decrease In Additions IncreaseDecreaseInAdditions	17337089	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	38939054	usd
CY2022	dcgo	Increase Decrease In Additions IncreaseDecreaseInAdditions	15449021	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	22969246	usd
CY2023Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	1365636	usd
CY2022Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	633363	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	3149231	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3796183	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3621413	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3240049	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3239331	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	12431293	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	29477500	usd
CY2023Q1	dcgo	Accrued Subcontractors AccruedSubcontractors	8889201	usd
CY2022Q4	dcgo	Accrued Subcontractors AccruedSubcontractors	8101150	usd
CY2023Q1	dcgo	Accrued General Expenses AccruedGeneralExpenses	7080279	usd
CY2022Q4	dcgo	Accrued General Expenses AccruedGeneralExpenses	11436462	usd
CY2023Q1	dcgo	Accrued Workers Compensation AccruedWorkersCompensation	6564201	usd
CY2022Q4	dcgo	Accrued Workers Compensation AccruedWorkersCompensation	3766469	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3688168	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4245838	usd
CY2023Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1312368	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1500717	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1014005	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	706528	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	706351	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	584203	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	629694	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	344417	usd
CY2023Q1	dcgo	Accrued Fuel And Maintenance AccruedFuelAndMaintenance	555528	usd
CY2022Q4	dcgo	Accrued Fuel And Maintenance AccruedFuelAndMaintenance	253243	usd
CY2023Q1	dcgo	Credit Card Payable CreditCardPayable	84623	usd
CY2022Q4	dcgo	Credit Card Payable CreditCardPayable	78838	usd
CY2023Q1	dcgo	Fica Medicare Liability FICAMedicareLiability	19664	usd
CY2022Q4	dcgo	Fica Medicare Liability FICAMedicareLiability	555166	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	30544082	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	31573031	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	29034	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	22559	usd
CY2021Q4	us-gaap	Advances To Affiliate AdvancesToAffiliate	12000000	usd
CY2021Q4	dcgo	Revolving Advances Description RevolvingAdvancesDescription	Each Revolving Advance would have borne interest at a per annum rate equal to the Wall Street Journal Prime Rate, as the same may have changed from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days in the applicable period.
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	90000000	usd
CY2022Q4	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	50000000	usd
CY2022Q4	dcgo	Line Of Credit Facility Sofr Loan Percentage LineOfCreditFacilitySOFRLoanPercentage	0.0125	pure
CY2022Q4	dcgo	Line Of Credit Facility Base Rate Loan Percentage LineOfCreditFacilityBaseRateLoanPercentage	0.0025	pure
CY2023Q1	dcgo	Installment Amount InstallmentAmount	64671	usd
CY2023Q1	us-gaap	Other Loans Payable OtherLoansPayable	1922223	usd
CY2022Q4	us-gaap	Other Loans Payable OtherLoansPayable	1901514	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	1922223	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1901514	usd
CY2023Q1	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	649808	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	664913	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	1272415	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1236601	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due In Next Rolling Twelve Months FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths	425309	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	478492	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due In Rolling Year Three FinanceLeaseLiabilityPaymentsDueInRollingYearThree	463573	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due In Rolling Year Four FinanceLeaseLiabilityPaymentsDueInRollingYearFour	384627	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	160977	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due In Rolling Year Five FinanceLeaseLiabilityPaymentsDueInRollingYearFive	9245	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due In Rolling After Year Five FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive	1922223	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	649808	usd
CY2023Q1	us-gaap	Other Notes Payable OtherNotesPayable	1272415	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	pure
CY2023Q1	us-gaap	Revenues Revenues	113002703	usd
CY2023Q1	us-gaap	Noninterest Income Other Operating Income NoninterestIncomeOtherOperatingIncome	6902587	usd
CY2023Q1	dcgo	Total Assets TotalAssets	407545176	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	3649329	usd
CY2023Q1	dcgo	Stock Compensation StockCompensation	8450016	usd
CY2023Q1	us-gaap	Noncurrent Assets NoncurrentAssets	108337168	usd
CY2022Q1	us-gaap	Revenues Revenues	117891552	usd
CY2022Q1	us-gaap	Noninterest Income Other Operating Income NoninterestIncomeOtherOperatingIncome	-10094565	usd
CY2022Q1	dcgo	Total Assets TotalAssets	325196304	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	2201021	usd
CY2022Q1	dcgo	Stock Compensation StockCompensation	1422937	usd
CY2022Q1	us-gaap	Noncurrent Assets NoncurrentAssets	31890703	usd
CY2022Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	40000000	usd
CY2022Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	536839	shares
CY2022Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3731712	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P10Y
CY2023Q1	dcgo	Share Based Compensation Arrangement By Share Based Payment Award Option Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedAndExpectedToVestExercisableNumber	3200000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11571308	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.11
CY2023Q1	dcgo	Weighted Average Remaining Contractual Life In Years WeightedAverageRemainingContractualLifeInYears	P9Y18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39389063	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	96101	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.6
CY2023Q1	dcgo	Options Shares Cancelled During The Year OptionsSharesCancelledDuringTheYear	-267539	shares
CY2023Q1	dcgo	Share Based Compensation Arrangements By Share Based Payment Award Options Expiration In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice	7.74
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11207668	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.15
CY2023Q1	dcgo	Weighted Average Remaining Contractual Life In Years Ending WeightedAverageRemainingContractualLifeInYearsEnding	P8Y8M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	45428463	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3153550	shares
CY2023Q1	dcgo	Weighted Average Exercise Price Options Vested And Exercisable WeightedAverageExercisePriceOptionsVestedAndExercisable	6.12
CY2023Q1	dcgo	Weighted Average Remaining Contractual Life In Years Options Vested And Exercisable WeightedAverageRemainingContractualLifeInYearsOptionsVestedAndExercisable	P7Y10M2D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9827324	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.15
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.04
CY2023Q1	dcgo	Stock Option Awards Granted StockOptionAwardsGranted	32118556	usd
CY2022	dcgo	Stock Option Awards Granted StockOptionAwardsGranted	41666564	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y
CY2022Q4	dcgo	Rs Us Unit RSUsUnit	305587	shares
CY2023Q1	dcgo	Weighted Average Grant Date Fair Value Per Rsu Beginning WeightedAverageGrantDateFairValuePerRSUBeginning	8.35
CY2023Q1	dcgo	Rs Us Vested During The Year RSUsVestedDuringTheYear	-80008	shares
CY2023Q1	dcgo	Weighted Average Grant Date Fair Value Per Rsu Vested During The Year WeightedAverageGrantDateFairValuePerRSUVestedDuringTheYear	7.71
CY2023Q1	dcgo	Rs Us Unit RSUsUnit	225579	shares
CY2023Q1	dcgo	Weighted Average Grant Date Fair Value Per Rsu Ending WeightedAverageGrantDateFairValuePerRSUEnding	8.58
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	136250	shares
CY2023Q1	dcgo	Weighted Average Grant Date Fair Value Per Rsu Vested And Unissued WeightedAverageGrantDateFairValuePerRSUVestedAndUnissued	7.71
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	225579	shares
CY2023Q1	dcgo	Weighted Average Grant Date Fair Value Per Rsu Nonvested WeightedAverageGrantDateFairValuePerRSUNonvested	8.58
CY2023Q1	dcgo	Total Fair Value TotalFairValue	0	usd
CY2023Q1	dcgo	Stockbased Compensation Expense StockbasedCompensationExpense	429675	usd
CY2023Q1	dcgo	Unrecognized Compensation Cost UnrecognizedCompensationCost	1934998	usd
CY2023Q1	dcgo	Weightedaverage Period WeightedaveragePeriod	P1Y1M6D
CY2019Q1	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.06	pure
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	756245	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	462625	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	336318	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	255096	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	1092563	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	717721	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	9375132	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	9074277	usd
CY2023Q1	dcgo	Operating Lease Assets OperatingLeaseAssets	9375132	usd
CY2022Q4	dcgo	Operating Lease Assets OperatingLeaseAssets	9074277	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2353383	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	8646803	usd
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M28D
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2325024	usd
CY2023Q1	dcgo	Lease Liability Net Of Non Current Portion LeaseLiabilityNetOfNonCurrentPortion	-7315226	usd
CY2022Q4	dcgo	Lease Liability Net Of Non Current Portion LeaseLiabilityNetOfNonCurrentPortion	-7040982	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9668609	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9366006	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M9D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0599	pure
CY2023Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	756245	usd
CY2022Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	462625	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	756245	usd
CY2023Q1	dcgo	Financing Lease Payments FinancingLeasePayments	744030	usd
CY2023Q1	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	8717048	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	7906966	usd
CY2023Q1	dcgo	Depreciation Expenses DepreciationExpenses	801083	usd
CY2022	dcgo	Depreciation Expenses DepreciationExpenses	855781	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1400000	usd
CY2023Q1	dcgo	Finance Leases Liability Payments Due FinanceLeasesLiabilityPaymentsDue	744030	usd
CY2022Q1	dcgo	Finance Leases Liability Payments Due FinanceLeasesLiabilityPaymentsDue	622575	usd
CY2023Q1	us-gaap	Lease Income LeaseIncome	744030	usd
CY2022Q1	us-gaap	Lease Income LeaseIncome	622575	usd
CY2023Q1	dcgo	Lease Rightofuse Assets LeaseRightofuseAssets	-9170429	usd
CY2022Q4	dcgo	Lease Rightofuse Assets LeaseRightofuseAssets	-9039663	usd
CY2023Q1	dcgo	Finance Lease Assets FinanceLeaseAssets	9170429	usd
CY2022Q4	dcgo	Finance Lease Assets FinanceLeaseAssets	9039663	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2773029	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2732639	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6061828	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5914164	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	8834857	usd
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0595	pure
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	853927	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-281949	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	809172	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-135606	usd
CY2022Q1	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	-58749	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-115286	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-83341	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	54839	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-214880	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4253	usd
CY2023Q1	us-gaap	Noninterest Income Other NoninterestIncomeOther	853927	usd
CY2022Q1	us-gaap	Noninterest Income Other NoninterestIncomeOther	-281949	usd
CY2023Q1	us-gaap	Other Income OtherIncome	214880	usd
CY2023Q1	us-gaap	Interest Income Foreign Deposits InterestIncomeForeignDeposits	637	usd
CY2023Q1	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	8496	usd
CY2023Q1	dcgo	Subcontractor Payments SubcontractorPayments	93311	usd
CY2022Q1	dcgo	Subcontractor Payments SubcontractorPayments	209153	usd
CY2023Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	125539	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	86555	usd
CY2023Q1	dcgo	Income Tax Expensebenefit IncomeTaxExpensebenefit	2129870	usd
CY2022Q1	dcgo	Income Tax Expensebenefit IncomeTaxExpensebenefit	-440179	usd
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3821	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0485	pure
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	1000000	usd
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	1000000	usd
CY2021Q2	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	1000000	usd
CY2023Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent		usd
CY2023Q1	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent		usd
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	dcgo	Stock Issued During Period Value Equity Cost StockIssuedDuringPeriodValueEquityCost		usd
CY2023Q1	dcgo	Noncontrolling Interest Contribution NoncontrollingInterestContribution		usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
CY2022Q1	dcgo	Loss On Disposal Of Assets LossOnDisposalOfAssets		usd
CY2022Q1	dcgo	Deferred Tax Asset DeferredTaxAsset		usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2022Q1	dcgo	Acquisition Of Leased Assets AcquisitionOfLeasedAssets		usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022Q1	dcgo	Gain From Ppp Loans Forgiveness GainFromPPPLoansForgiveness		usd
CY2022Q1	dcgo	Noncash Investing Activities Acquisitions Of Business Funded By Acquisition Payable NoncashInvestingActivitiesAcquisitionsOfBusinessFundedByAcquisitionPayable		usd
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2022Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	dcgo	Weighted Average Remaining Contractual Life In Years Granted Vested During The Year WeightedAverageRemainingContractualLifeInYearsGrantedVestedDuringTheYear
CY2023Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued		usd
CY2023Q1	dcgo	Weighted Average Remaining Contractual Life In Years Exercised During The Year WeightedAverageRemainingContractualLifeInYearsExercisedDuringTheYear
CY2023Q1	dcgo	Aggregate Intrinsic Value Exercised During The Years AggregateIntrinsicValueExercisedDuringTheYears		usd
CY2023Q1	dcgo	Weighted Average Remaining Contractual Life In Years Cancelled During The Year WeightedAverageRemainingContractualLifeInYearsCancelledDuringTheYear
CY2023Q1	dcgo	Aggregate Intrinsic Value Cancelled During The Year AggregateIntrinsicValueCancelledDuringTheYear		usd
CY2023Q1	dcgo	Rs Us Granted RSUsGranted		shares
CY2023Q1	dcgo	Weighted Average Grant Date Fair Value Per Rsu Granted WeightedAverageGrantDateFairValuePerRSUGranted
CY2023Q1	us-gaap	Short Term Lease Payments ShortTermLeasePayments		usd
CY2022Q1	us-gaap	Short Term Lease Payments ShortTermLeasePayments		usd
CY2023Q1	us-gaap	Debt Conversion Original Debt Due Date Of Debt Year DebtConversionOriginalDebtDueDateOfDebtYear	2029
CY2023Q1	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet		usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001822359

Files In Submission

Name	View Source	Status
dcgo-20230331_cal.xml	Edgar Link	unprocessable
dcgo-20230331_def.xml	Edgar Link	unprocessable
0001213900-23-037709-index-headers.html	Edgar Link	pending
0001213900-23-037709-index.html	Edgar Link	pending
0001213900-23-037709.txt	Edgar Link	pending
0001213900-23-037709-xbrl.zip	Edgar Link	pending
dcgo-20230331.xsd	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
f10q0323ex10-1_docgoinc.htm	Edgar Link	pending
f10q0323ex31-1_docgoinc.htm	Edgar Link	pending
f10q0323ex31-2_docgoinc.htm	Edgar Link	pending
f10q0323ex32-1_docgoinc.htm	Edgar Link	pending
f10q0323ex32-2_docgoinc.htm	Edgar Link	pending
f10q0323_docgoinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
dcgo-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dcgo-20230331_lab.xml	Edgar Link	unprocessable
f10q0323_docgoinc_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DCGO
DocGo Inc. Stock $dcgo

2023 Q2 Form 10-Q Financial Statement

#000121390023037709 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DCGO DocGo Inc. Stock $dcgo

2023 Q2 Form 10-Q Financial Statement

#000121390023037709 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DCGO
DocGo Inc. Stock $dcgo